These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9186920

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.
    Tani M, Horvath KV, Lamarche B, Couture P, Burnett JR, Schaefer EJ, Asztalos BF.
    Atherosclerosis; 2016 Oct; 253():7-14. PubMed ID: 27573733
    [Abstract] [Full Text] [Related]

  • 28. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall A.
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Correction of hypoalphalipoproteinemia in LDL receptor-deficient rabbits by lecithin:cholesterol acyltransferase.
    Brousseau ME, Wang J, Demosky SJ, Vaisman BL, Talley GD, Santamarina-Fojo S, Brewer HB, Hoeg JM.
    J Lipid Res; 1998 Aug; 39(8):1558-67. PubMed ID: 9717715
    [Abstract] [Full Text] [Related]

  • 31. Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.
    Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JA, Stuart WD, Rubin EM, Ng DS.
    J Lipid Res; 1999 Jul; 40(7):1276-83. PubMed ID: 10393212
    [Abstract] [Full Text] [Related]

  • 32. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency.
    Chroni A, Duka A, Kan HY, Liu T, Zannis VI.
    Biochemistry; 2005 Nov 01; 44(43):14353-66. PubMed ID: 16245952
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Deletion of amino acids Glu146-->Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid.
    Lindholm EM, Bielicki JK, Curtiss LK, Rubin EM, Forte TM.
    Biochemistry; 1998 Apr 07; 37(14):4863-8. PubMed ID: 9538003
    [Abstract] [Full Text] [Related]

  • 38. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice.
    Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setälä K, Walsh A, Breslow JL.
    J Clin Invest; 1993 Apr 07; 91(4):1665-71. PubMed ID: 8473509
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers.
    Daum U, Leren TP, Langer C, Chirazi A, Cullen P, Pritchard PH, Assmann G, von Eckardstein A.
    J Lipid Res; 1999 Mar 07; 40(3):486-94. PubMed ID: 10064737
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.